Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.715 USD | -2.00% | -1.11% | -25.09% |
Sales 2024 * | 184M 15.39B | Sales 2025 * | 219M 18.3B | Capitalization | 259M 21.65B |
---|---|---|---|---|---|
Net income 2024 * | -55M -4.59B | Net income 2025 * | -27M -2.25B | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.18 x |
P/E ratio 2024 * |
-4.55
x | P/E ratio 2025 * |
-9.55
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.26% |
Latest transcript on Xeris Biopharma Holdings, Inc.
1 day | -2.00% | ||
1 week | -1.11% | ||
Current month | -20.35% | ||
1 month | -17.74% | ||
3 months | -33.82% | ||
6 months | +5.41% | ||
Current year | -25.09% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 01/05/01 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/21/05 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05/21/05 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05/21/05 |
Marla Persky
BRD | Director/Board Member | 68 | 05/21/05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - | |
0.00% | 147 M€ | +4.88% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.765 | +0.86% | 70 386 |
26/24/26 | 1.75 | +2.94% | 870,181 |
25/24/25 | 1.7 | -3.41% | 894,039 |
24/24/24 | 1.76 | -1.12% | 712,941 |
23/24/23 | 1.78 | 0.00% | 1,345,307 |
Delayed Quote Nasdaq, April 29, 2024 at 07:15 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.09% | 259M | |
+25.83% | 661B | |
+26.92% | 566B | |
-6.19% | 352B | |
+20.84% | 332B | |
+3.84% | 283B | |
+14.32% | 231B | |
+5.22% | 200B | |
-8.96% | 195B | |
-5.02% | 145B |
- Stock Market
- Equities
- XERS Stock